ATNX News and Press, Athenex Inc. From 08/06/21

Image source: The Motley Fool. Athenex, inc (NASDAQ: ATNX) Q2 2021 Earnings Call Aug 6, 2021 , 10:00 p.m. ET Operator Continue reading For further details see: Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript

Fastly FSLY -23% on Q2 earnings release  Karyopharm Therapeutics KPTI -18% on Q2 earnings release  Fiverr International FVRR -17% on Q2 earnings release Etsy ETSY -13% on Q2 earnings release Maxar Technologies MAXR -13% on Q2 earning...

Athenex (NASDAQ:ATNX): Q2 GAAP EPS of -$0.33 beats by $0.08. Revenue of $21.92M (-45.4% Y/Y) misses by $1.52M. Press Release For further details see: Athenex EPS beats by $0.08, misses on revenue

Updated investors on FDA Type A Meeting for oral paclitaxel Klisyri ® approved by the European Commission in July 2021 KUR-501 GD2 CAR-NKT Phase 1 data in neuroblastoma presented at ASGCT 2021 Abstract for oral paclitaxel + pembrolizumab Phase 1 combination study acce...

Athenex Inc. (NASDAQ:ATNX) traded today at a new 52-week low of $3.53. So far today approximately 669,000 shares have been exchanged, as compared to an average 30-day volume of 1.4 million shares. Over the past year, Athenex Inc. has traded in a range of $3.53 to $15.24 and is now at $3....

Athenex (ATNX) perks up 6.7% premarket after entering into licensing agreements and strategic partnerships with Seqirus Pty Ltd, a subsidiary of CSL Limited, and AVIR Pharma ((AVIR)) for tirbanibulin. Under the terms of agreements, Seqirus will have an exclusive license to commercia...

BUFFALO, N.Y., July 26, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the Company has enter...

BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provi...

BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall...

BUFFALO, N.Y., July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company held a Ty...